Related Experiment Video

Updated: Mar 2, 2026

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

18.7K

Downregulation of ATP1A1 promotes cancer development in renal cell carcinoma

Dan Zhang1, Peng Zhang2, Pengbo Yang1

  • 1State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, No.17 Section 3, People's South Road, Chengdu, 610041 People's Republic of China.

Clinical Proteomics
|May 10, 2017
PubMed
Abstract

Insights

The Na+/K+-ATPase α1 subunit (ATP1A1) is decreased in renal cell carcinoma (RCC) and acts as a tumor suppressor. Higher ATP1A1 expression correlates with better patient survival, inhibiting RCC progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Aberrant Na+/K+-ATPase α1 subunit (ATP1A1) expression is linked to various cancers.
  • The specific role of ATP1A1 in renal cell carcinoma (RCC) progression remains unclear.

Purpose of the Study:

  • To investigate ATP1A1 expression and its functional significance in RCC.
  • To elucidate the molecular mechanisms underlying ATP1A1's role in renal cancer.

Main Methods:

  • Quantitative proteomics (LC-MS/MS) and immunohistochemistry were used to assess ATP1A1 expression in 80 RCC and adjacent non-tumor tissues.
  • Cellular assays (CCK-8, Boyden chamber, flow cytometry) measured proliferation, migration, and apoptosis.
  • Reactive oxygen species (ROS) production and the Raf/MEK/ERK pathway were analyzed.

Main Results:

  • ATP1A1 expression was significantly decreased in RCC tissues compared to non-tumor tissues.
  • Positive ATP1A1 expression in RCC patients correlated with longer overall survival.
  • Overexpression of ATP1A1 inhibited RCC cell proliferation and migration, increased ROS production, and suppressed the Raf/MEK/ERK pathway, promoting apoptosis.

Conclusions:

  • ATP1A1 acts as a suppressor protein in renal cell carcinoma.
  • Decreased ATP1A1 expression is associated with RCC progression and poorer prognosis.
  • ATP1A1 represents a potential therapeutic target for renal cancer.
Keywords:
DownregulationNa+/K+-ATPase α1 subunitRenal cell carcinoma

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.3K
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

34.2K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
6.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.9K